- Home
- NWAX vs AQST Comparison
NWAX vs AQST Comparison
Compare NWAX & AQST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NWAX | AQST |
|---|---|---|
| Founded | 2025 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 502.0M | 521.0M |
| IPO Year | N/A | 2007 |
Fundamental Metrics
Financial Performance| Metric | NWAX | AQST |
|---|---|---|
| Price | $10.05 | $4.01 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $9.00 |
| AVG Volume (30 Days) | 75.8K | ★ 1.9M |
| Earning Date | 01-01-0001 | 03-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $67,430,000.00 |
| Revenue This Year | N/A | $14.23 |
| Revenue Next Year | N/A | $58.36 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 0.77 |
| 52 Week Low | $10.00 | $2.20 |
| 52 Week High | $10.25 | $7.55 |
Technical Indicators
Market Signals| Indicator | NWAX | AQST |
|---|---|---|
| Relative Strength Index (RSI) | 46.21 | 46.55 |
| Support Level | $10.00 | $3.69 |
| Resistance Level | $10.10 | $4.46 |
| Average True Range (ATR) | 0.03 | 0.21 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 50.00 | 23.44 |
Price Performance
Historical ComparisonAbout NWAX New America Acquisition I Corp. Class A Common Stock
New America Acquisition I Corp is a blank check company formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses, which it refers to throughout this prospectus as its initial Business Combination.
About AQST Aquestive Therapeutics Inc.
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif, and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.